MAPT and neurodegenerative disease: Plasma p-tau181 has a comparable specificity to both CSF Aβ1-42/Aβ1-40 ratio and CSF total tau and is only marginally inferior to CSF p-tau181 combined with tau-PET imaging in differentiating AD dementia from non-AD neurodegenerative diseases [58,59].